Skip to main content

Moderna, Inc. Stand-ready manufacturing revenue

  • MRNA · Nasdaq
  • Biotechnology
  • S&P 500
$223.37−3.45%Close 13 Nov 2026 · Market value $87.52B

Stand-ready manufacturing revenue at Moderna, Inc. came to $31.0M for the quarter to 30 Sep 2026, up 55.0% from a year earlier.

As Moderna, Inc. reported it in its earnings release and quarterly or annual report, compiled and checked by AapWire. Latest figure filed 6 Nov 2026.

By quarter

$12.0MMar 2025$17.0MJun 2025$20.0MSep 2025$31.0MDec 2025$32.0MMar 2026$31.0MJun 2026$31.0MSep 2026
Moderna, Inc. Stand-ready manufacturing revenue, every reported period
Period endingStand-ready manufacturing revenueChange on a yearFiled
30 Sep 2026$31.0Mup 55.0%6 Nov 2026
30 Jun 2026$31.0Mup 82.4%31 Jul 2026
31 Mar 2026$32.0Mup 166.7%1 May 2026
31 Dec 2025$31.0M—20 Feb 2026
30 Sep 2025$20.0M—6 Nov 2025
30 Jun 2025$17.0M—1 Aug 2025
31 Mar 2025$12.0M—1 May 2025

Definition

Revenue from this part of the business, as the company names and reports it in its results. Each figure is read from the table or sentence the company printed and kept with its scale and decimals; see data and methodology.

Other operating KPIs of Moderna, Inc.: COVID revenue · RSV revenue · Collaboration Arrangement, Including Arrangements With Affiliate revenue · Grant revenue · United States revenue · Rest of world revenue · Europe revenue · financial statements

Every KPI and segment of MRNA, in the terminal.

Ten years of operating figures, segments, guidance against results, charts and alerts on each new release.